Advertisement


Brian C. Baumann, MD, on Bladder Cancer: Trial Results on Adjuvant Chemoradiotherapy vs Adjuvant Radiotherapy Alone

2019 Genitourinary Cancers Symposium

Advertisement

Brian C. Baumann, MD, of Washington University School of Medicine, discusses phase III study findings on adjuvant sequential chemotherapy plus radiotherapy vs adjuvant radiotherapy alone for locally advanced bladder cancer after radical cystectomy (Abstract 351).



Related Videos

Prostate Cancer

Nicholas J. van As, MD, on Prostate Cancer: Results From the PACE-B Trial Comparing Radiotherapy Techniques

Nicholas J. van As, MD, of The Royal Marsden NHS Foundation Trust, discusses an analysis of acute toxicity in the PACE-B study, which compared stereotactic body radiotherapy ...

Kidney Cancer
Immunotherapy

Rana R. McKay, MD, on Renal Cell Carcinoma: Results From a Trial on Atezolizumab and Bevacizumab

Rana R. McKay, MD, of the University of California, San Diego, discusses phase II study findings on atezolizumab and bevacizumab in non–clear cell renal cell carcinoma and cl...

Kidney Cancer

Ignacio Duran, MD, PhD, on Renal Cell Carcinoma: Results From the METEOR Trial on Cabozantinib vs Everolimus

Ignacio Duran, MD, PhD, of the Hospital Universitario Marqués de Valdecilla, discusses an overall survival analysis of the phase III METEOR trial of cabozantinib vs everolimu...

Prostate Cancer

Howard I. Scher, MD, on Prostate Cancer: Circulating Tumor Cells as a Surrogate Endpoint for Survival

Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials o...

Kidney Cancer

Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses phase III findings on a comparison of tivozanib and sorafenib in patients with refractory advan...

Advertisement

Advertisement



;
Advertisement